Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 is drawing significant interest across the industry.
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026.
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- Indian Wells: Britons Jacob Fearnley and Sonay Kartal pick up opening-round wins at BNP Paribas Open
- Love on the big screen
- Heart Surgery Update for Biathlon Star After Unfortunate Winter Olympics Withdraw
- Uzbekistan expands domestic capacity for complex pediatric surgery
Source: Original →